Cargando…
Still the Joker in the Pack: When to Take Out Cyclosporine in the Game?
Autores principales: | Resál, Tamás, Szántó, Kata, Rutka, Mariann, Farkas, Klaudia, Molnár, Tamás |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10673650/ https://www.ncbi.nlm.nih.gov/pubmed/33742654 http://dx.doi.org/10.1093/ibd/izab066 |
Ejemplares similares
-
The complex relationship between viruses and inflammatory bowel disease – review and practical advices for the daily clinical decision-making during the SARS-CoV-2 pandemic
por: Farkas, Klaudia, et al.
Publicado: (2021) -
Nationwide experiences with trough levels, durability, and disease activity among inflammatory bowel disease patients following COVID-19 vaccination
por: Resál, Tamás, et al.
Publicado: (2023) -
Ustekinumab is associated with superior treatment persistence but not
with higher remission rates versus vedolizumab in patients with
refractory Crohn’s disease: results from a multicentre cohort
study
por: Bacsur, Péter, et al.
Publicado: (2022) -
Effect of COVID-19 pandemic on the workflow of endoscopy units: an international survey
por: Resál, Tamás, et al.
Publicado: (2021) -
Conception and reality: Outcome of SARS-CoV-2 infection and vaccination among Hungarian IBD patients on biologic treatments
por: Resál, Tamás, et al.
Publicado: (2022)